Open AccessmiR-29b is an indicator of prognosis in breast cancer patients
Author(s) -
Yoshiaki Shinden,
Tomohiro Iguchi,
Sayuri Akiyoshi,
Hiroki Ueo,
Masami Ueda,
Hidenari Hirata,
Shotaro Sakimura,
Ryutaro Uchi,
Yuki Takano,
Hidetoshi Eguchi,
Keizō Sugimachi,
Yuko Kijima,
Shoji Natsugoe,
Koshi Mimori
Publication year - 2015
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2015.565
Subject(s) - breast cancer , oncogene , carcinogenesis , oncology , cancer research , cancer , microrna , estrogen receptor , medicine , metastasis , progesterone receptor , ca15 3 , biology , cell cycle , gene , biochemistry
MicroRNA-29b ( miR-29b ) targets numerous important genes that mediate carcinogenesis and tumor development in breast cancer in vitro and in vivo . The aim of the present study was to determine the clinical significance of miR-29b expression in primary breast cancer patients. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) of miR-29b and certain target genes of miR-29b , such as DNA methyltransferase 3A ( DNMT3A ), ten-eleven translocation 1 ( TET1 ) and thymine DNA glycosylase ( TDG ), was performed in 94 primary breast cancer samples. Low expression of miR-29b in primary tumors was significantly associated with poorer disease-free survival (DFS) (P=0.0075) and overall survival (OS) (p=0.0012). Multivariate analysis indicated that miR-29b expression was an independent prognostic factor for OS [relative risk=15.6 (2.33-348), P=0.0026]. In addition, a significant inverse correlation was identified between the expression levels of DNMT3A and miR-29b in estrogen receptor-positive breast cancer patients (P=0.027). To the best of our knowledge, this is the first study to investigate the clinicopathological significance of miR-29b in breast cancer cases and miR-29b is shown to act as a tumor suppressive microRNA in breast cancer and as a potential marker for recurrence and metastasis in breast cancer patients.